Johnson & Johnson (JNJ) on Wednesday announced plans to construct a cell therapy manufacturing facility in Pennsylvania at an investment of more than $1B, further boosting its business operations in the state.
The new facility to be built in Montgomery County, PA, is part of J&J’s (JNJ) efforts to spend $55B by 2029 to expand its presence in manufacturing, R&D, and technology in the U.S.
The investment is expected to generate over 500 biomanufacturing jobs and more than 4,000 construction jobs for the local economy, according to the company.
Backed by 10 facilities spanning over 2M square feet, J&J (JNJ) runs manufacturing, R&D, and office operations in Pennsylvania, adding roughly $10B to the state annually.
“For 140 years, Johnson & Johnson has been a leading innovator in American healthcare, and we are honored to continue advancing that legacy in Pennsylvania,” CEO Joaquin Duato remarked.